Saad Z. Usmani, MD, MBA, FACP, Talks About Durable and Deep Responses of Cilta-Cel for Patients With Multiple Myeloma

Video

Usmani noted the strong overall response and stringent complete response rates observed with ciltacabtagene autoleucel for multiple myeloma at a median follow-up of 18 months.

At the 2021 European Hematology Association (EHA) Annual Meeting, CancerNetwork® spoke with Saad Z. Usmani, MD, MBA, FACP, of the Levine Cancer Institute in Charlotte, North Carolina, about his main takeaway from the CARTITUDE-1 trial, citing durable and deep responses experienced by patients with multiple myeloma who were treated with ciltacabtagene autoleucel (cilta-cel).

Transcription:

The main takeaway is that at a longer median follow-up of 18 months, cilta-cel appears to be very active. It’s leading to early deep and durable responses in heavily pretreated [patients with myeloma] with an overall response rate of 98% [and a] stringent CR rate of 80%. In the evaluable patients for [minimal residual disease (MRD)] negativity by [next-generation sequencing] at 10-5, 92% were MRD negative. [There was an] 18-month [progression-free survival rate] of 66% and [overall survival] rate of 81%. [These were] very impressive results in a heavily pretreated patient population. We look forward to getting more data in different settings within myeloma, including earlier relapse and frontline.

Reference

Weisel K, Martin T, Krishnan A, et al. Comparison of Ciltacabtagene Autoleucel (Cilta-cel) in CARTITUDE-1 Versus Standard of Care in Triple-Class Exposed Multiple Myeloma Patients in Clinical Trials of Daratumumab. Presented at: 2021 European Hematologic Association Congress; Virtual. June 9-17, 2021. Abstract EP977.

Related Videos
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.
A panel of 3 experts on multiple myeloma
A panel of 3 experts on multiple myeloma
Dostarlimab plus chemotherapy appears to yield favorable overall survival in patients with mismatch repair proficient endometrial cancer.
Some patients with large B-cell lymphoma may have to travel a great distance for an initial evaluation for CAR T-cell therapy.
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Education is essential to referring oncologists manage toxicities associated with CAR T-cell therapy for patients with large B-cell lymphoma.
Related Content